Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention-Reference-Cited by-同舟云学术

Effect of P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy on Cardiovascular Events in Patients Undergoing Percutaneous Coronary Intervention

Published:2019-06-25 Issue:24 Volume:321 Page:2428
ISSN:0098-7484
Container-title:JAMA
language:en
Short-container-title:JAMA

Author:

Hahn Joo-Yong¹,Song Young Bin¹,Oh Ju-Hyeon²,Chun Woo Jung²,Park Yong Hwan²,Jang Woo Jin²,Im Eul-Soon³,Jeong Jin-Ok⁴,Cho Byung Ryul⁵,Oh Seok Kyu⁶,Yun Kyeong Ho⁶,Cho Deok-Kyu⁷,Lee Jong-Young⁸,Koh Young-Youp⁹,Bae Jang-Whan¹⁰,Choi Jae Woong¹¹,Lee Wang Soo¹²,Yoon Hyuck Jun¹³,Lee Seung Uk¹⁴,Cho Jang Hyun¹⁵,Choi Woong Gil¹⁶,Rha Seung-Woon¹⁷,Lee Joo Myung¹,Park Taek Kyu¹,Yang Jeong Hoon¹,Choi Jin-Ho¹,Choi Seung-Hyuck¹,Lee Sang Hoon¹,Gwon Hyeon-Cheol¹,

Affiliation:

1. Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

2. Department of Cardiology, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine, Changwon, Korea

3. Division of Cardiology, Dongsuwon General Hospital, Suwon, Korea

4. Chungnam National University Hospital, Daejeon, Korea

5. Division of Cardiology, Kangwon National University Hospital, Chuncheon, Korea

6. Department of Cardiovascular Medicine, Regional Cardiocerebrovascular Center, Wonkwang University Hospital, Iksan, Korea

7. Division of Cardiology, Department of Internal Medicine, Myongji Hospital, Goyang, Korea

8. Division of Cardiology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea

9. Department of Internal Medicine, Chosun University Hospital, Gwangju, Korea

10. Department of Internal Medicine, College of Medicine, Chungbuk National University Hospital, Cheongju, Korea

11. Eulji General Hospital, Seoul, Korea

12. Chung-Ang University Hospital, Seoul, Korea

13. Keimyung University Dongsan Medical Center, Daegu, Korea

14. Kwangju Christian Hospital, Gwangju, Korea

15. St Carollo Hospital, Suncheon, Korea

16. Konkuk University Chungju Hospital, Chungju, Korea

17. Korea University Guro Hospital, Seoul, Korea

Publisher

American Medical Association (AMA)

Subject

General Medicine

Link

https://jamanetwork.com/journals/jama/article-pdf/321/24/2428/17826923/jama_hahn_2019_oi_190061.pdf

Reference33 articles.

1. 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.;Levine;J Am Coll Cardiol,2016

2. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).;Valgimigli;Eur Heart J,2018

3. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study.;Gwon;Circulation,2012

4. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.;Feres;JAMA,2013

5. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials.;Palmerini;Lancet,2015

Cited by 427 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Randomized evaluation of 5-month Ticagrelor monotherapy after 1-month dual-antiplatelet therapy in patients with acute coronary syndrome treated with drug-coated balloons: REC-CAGEFREE II trial rationale and design;BMC Cardiovascular Disorders;2024-01-20

2. De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a systematic review and network meta-analysis;BMJ Evidence-Based Medicine;2024-01-19

3. Aspirin-free antiplatelet strategies after percutaneous coronary interventions;European Heart Journal;2024-01-18

4. Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions;Pharmacogenomics;2024-01-17

5. Duration of Dual Antiplatelet Treatment After Percutaneous Coronary Intervention in Patients With Diabetes: A Systematic Review and Meta-analysis;Journal of Cardiovascular Pharmacology;2024-01